Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus‐related carcinoma and prescribed anti‐viral therapy

Suzanne Sheppard‐Law, Iryna Zablotska‐Manos, Melissa Kermeen, Susan Holdaway, Alice Lee, Jacob George, Amany Zekry and Lisa Maher

Journal of Clinical Nursing, 2018, vol. 27, issue 13-14, 2673-2683

Abstract: Aims and objectives To investigate hepatocellular carcinoma screening utilisation and factors associated with utilisation among patients prescribed hepatitis B virus anti‐viral therapy and at risk of hepatocellular carcinoma. Background The incidence of hepatocellular carcinoma has increased in Australia over the past three decades with chronic hepatitis B virus infection a major contributor. hepatocellular carcinoma surveillance programs aim to detect cancers early enabling curative treatment options, longer survival and longer times to recurrence. Design Multi‐site cross‐sectional survey. Methods An online study questionnaire was administered to eligible participants attending three Sydney tertiary hospitals. Data were grouped into six mutually exclusive hepatocellular carcinoma risk factor categories as per American Association for the Study of Liver Diseases guidelines. All analyses were undertaken in STATA. Logistic regression was used to assess the associations between covariates and screening utilisation. Multivariate models described were assessed using the Hosmer–Lemeshow goodness of fit. Results Of the 177 participants, 137 (77.4%) self‐reported that US had been performed in the last six months. Awareness that screening should be performed and knowing the correct frequency of US screening were independently associated with screening utilisation. Participants who knew that screening should be undertaken were three times more likely to have had pretreatment education or were prescribed hepatitis B virus anti‐viral treatment for >4 years. Participants reporting a family history of hepatocellular carcinoma were less likely to know that screening should be undertaken every 6 months. Conclusion While utilisation of hepatocellular carcinoma surveillance programs was higher in this study than in previous reports, strategies to further improve surveillance remain necessary. Relevance to clinical practice Findings from this research form the basis for proposing strategies to improve utilisation of hepatocellular carcinoma screening, inform hepatitis B virus‐related clinical practice and for the delivery of care and nursing education to people receiving hepatitis B virus anti‐viral therapy and at risk of developing hepatocellular carcinoma.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/jocn.14367

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:jocnur:v:27:y:2018:i:13-14:p:2673-2683

Access Statistics for this article

More articles in Journal of Clinical Nursing from John Wiley & Sons
Bibliographic data for series maintained by Wiley Content Delivery ().